Fluorene Derivative Antiviral Against HCV Mutants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HCV drugs face challenges due to high mutation rates of the hepatitis C virus, leading to drug resistance and limited efficacy, especially in treating chronic infections and liver diseases caused by HCV mutants.
Innovation Solution
A fluorene derivative with specific structural features is developed, which acts as an antiviral agent effective against both HCV and its mutants, including double mutants, by inhibiting key viral replication mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-HCV drugs are used to treat HCV infection, then viral replication is inhibited, but drug resistance develops due to high mutation rates of HCV
Solution Approach 1:
The fluorene derivative is designed to target multiple HCV proteins including NS3, NS4A, NS5A, and NS5B simultaneously, providing broad-spectrum antiviral activity against various HCV genotypes and mutants. This multi-target mechanism prevents the virus from developing resistance through single mutation events.
Solution Approach 2:
The compound combines a fluorene core structure with multiple functional groups including amide, carboxylic acid, and heterocyclic moieties that interact with different viral proteins. This composite molecular structure enables simultaneous binding to multiple targets, overcoming drug resistance.
2Reliability
If combination therapy of interferon and ribavirin is used, then antiviral effect is achieved, but serious side effects occur and treatment cost increases
Solution Approach 1:
The invention separates the antiviral function from the harmful side effects by designing a small molecule fluorene derivative that directly targets viral proteins, eliminating the need for interferon and ribavirin combination therapy. This segmented approach achieves antiviral efficacy without the immunomodulatory side effects of interferon.
Solution Approach 2:
The fluorene derivative is designed as a stable small molecule compound that can be administered orally, replacing expensive and complex combination therapies. The compound provides sustained antiviral activity without requiring continuous expensive treatment regimens.
3Reliability
If anti-HCV drugs target specific viral proteins, then viral replication is blocked, but HCV mutants with resistance mutations are not effectively treated
Solution Approach 1:
The fluorene derivative simultaneously targets NS3 protease, NS4A cofactor, NS5A phosphoprotein, and NS5B RNA polymerase, providing universal antiviral activity against all major HCV proteins. This multi-functional approach ensures effectiveness against both wild-type and mutant viruses.
Solution Approach 2:
The compound exhibits dynamic binding interactions with multiple viral proteins, adapting to different viral strains and mutants. The flexible molecular structure allows the drug to maintain binding affinity despite viral mutations, providing sustained efficacy.
Data Source
AI summary
The present invention relates to a fluorene derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the same as an effective ingredient for preventing or treating HCV-related disease. A fluorene derivative according to the present invention is identified to exhibit an antiviral performance against not only HCV, but also highly against HCV mutants, particularly double mutants and thus can be used in a pharmaceutical composition for prevention or treatment of HCV-caused liver disease, such as acute hepatitis C, chronic hepatitis C, liver cirrhosis, hepatocellular cancer, etc., particularly, liver disease caused by mutants of HCV. The derivative can be useful in a pharmaceutical composition for prevention or treatment of HCV-related liver disease by which the problem of resistant mutation against conventional therapeutic agents is solved.